查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007874

生物感測器診斷市場預測至2034年—按產品類型、技術、分銷管道、應用、最終用戶和地區分類的全球分析

Biosensor Diagnostics Market Forecasts to 2034 - Global Analysis By Product Type, Technology, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球生物感測器診斷市場規模將達到 286 億美元，並在預測期內以 15.3% 的複合年成長率成長，到 2034 年將達到 894 億美元。

生物感測器診斷是指將酵素、抗體、核酸或活細胞等生物辨識元件與物理化學轉換器結合，用於檢測和定量臨床、環境、食品安全和研究領域中的生物分析物的分析儀器。這些儀器基於電化學、光學、壓電或熱檢測原理運行，並產生與目標分析物濃度成正比的訊號。典型應用包括連續血糖監測、感染疾病檢測、心臟生物標記定量以及即時檢測 (PoC) 和檢查室環境中的癌症診斷篩檢。

即時診斷的需求

隨著全球醫療系統優先發展分散式檢查能力，以減少檢查室處理延遲並實現即時臨床決策，即時診斷的需求成為市場的主要驅動力。基於生物感測器的快速診斷設備在檢測血糖值、肌鈣蛋白和感染疾病病原體方面，已展現出與檢查室分析儀相當的臨床準確性。需要持續監測的慢性疾病（尤其是糖尿病）的日益普遍，為服務居家照護和門診機構的生物感測器製造商帶來了來自耗材和設備更換的永續收入來源。

感測器精度和校準限值

感測器精度和校準方面的限制仍然是持續存在的技術難題，尤其是在可連續佩戴的生物感測器中，這些感測器需要在多種生理條件下運行，包括出汗、體溫波動和用戶移動等因素的影響。長時間配戴會導致電化學感測器漂移，從而降低臨床可靠性，需要頻繁重新校準和更換，增加使用者負擔。監管機構要求證明其臨床等效性與檢查室參考方法相符，這需要進行嚴格的檢驗測試，從而推高研發成本並延長產品上市時間。

穿戴式連續監測市場

穿戴式連續監測技術蘊藏著巨大的成長潛力，微型生物感測器與消費級穿戴式平台的融合，在傳統臨床診斷之外，創造了一個價值數十億美元的潛在市場。連續血糖監測的應用範圍正從第1型糖尿病擴展到第2型糖尿病，甚至包括糖尿病前期健康管理。基於汗液的電化學生物感測器能夠進行非侵入性的電解質和代謝物監測，目前正進入商業化開發階段，其在運動表現和遠端患者監護等領域的應用吸引了許多投資者和戰略合作夥伴的濃厚興趣。

來自仿冒品產品的競爭

假冒仿冒品生物感測器產品的氾濫對市場健康構成重大威脅。發展中國家不受監管的製造商以遠低於市價的價格供應檢驗的診斷設備，嚴重損害了臨床對生物感測器診斷的信任。主要新興市場經濟體監管執法能力的不足，使得不合格產品得以透過醫院和藥房的通路流通。低品質產品的價格競爭壓力正在擠壓高階生物感測器製造商的利潤空間，使其難以證明自身技術具有顯著優勢。

新冠疫情的影響：

新冠疫情徹底改變了生物感測器診斷市場，對快速抗原和抗體檢測生物感測器設備的需求空前高漲，推動了產能提升，並為監管機構的緊急使用授權樹立了先例。疫情期間對即時檢測基礎設施的投資已深深融入醫療保健體系。即使在後疫情時代，呼吸道病原體生物感測器和穿戴式病患監測解決方案的應用，也持續受益於疫情期間建立的製度化遠距醫療模式。

在預測期內，奈米機械生物感測器領域預計將成為最大的細分市場。

由於奈米機械生物感測器具有卓越的靈敏度，預計在預測期內將佔據最大的市場佔有率。這種靈敏度使其能夠檢測癌症生物標記和病原體診斷應用中至關重要的超低濃度閾值物。奈米機械懸臂樑和共振器平台能夠實現飛莫耳級的偵測能力，這是傳統電化學設計無法達到的。奈米機械原理與下一代臨床實驗室設備和研究診斷儀器的日益整合，正推動學術機構和臨床檢查室的持續採購。

預計在預測期內，基於酵素的生物感測器領域將呈現最高的複合年成長率。

在預測期內，酶基生物感測器領域預計將呈現最高的成長率，這主要得益於連續血糖監測設備的日益普及、照護現場中乳酸和尿酸檢測的廣泛應用，以及用於環境毒素檢測的新型酶生物感測器的開發。酵素固定化技術的進步正在延長感測器的運作並降低性能變異性。領先的診斷設備製造商正在加大對酵素生物感測器耗材平台的投資，這些平台支援基於訂閱的經營模式，從而產生持續的收入。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率。這主要歸功於糖尿病的高發生率推動了持續血糖監測的普及，完善的家庭診斷保險報銷體系，以及開發尖端生物感測器技術的成熟基礎設施。美國食品藥物管理局（FDA）制定的醫療設備監管路徑正在加速生物感測器的商業化進程。雅培和德康等公司透過不斷改進產品和擴展其穿戴式診斷平台產品組合，保持其市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於印度和中國糖尿病患者數量的快速成長、對照護現場診斷基礎設施投資的增加以及政府支持國內醫療設備製造的各項計劃。中國國家藥品監督管理局正在簡化體外診斷醫療設備的核准流程，加速生物感測器產品的市場推廣。區域製造成本優勢正推動生物感測器產能從西方市場轉移。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球生物感測器診斷市場：依產品類型分類

  • 電化學生物感測器
  • 光學生物感測器
  • 壓電感測器
  • 熱生物感測器
  • 奈米機械生物感測器
  • 穿戴式生物感測器
  • 其他產品類型

第6章 全球生物感測器診斷市場：依技術分類

  • 基於酵素的生物感測器
  • 免疫感測器
  • DNA生物感測器
  • 奈米生物感測器
  • 微流體生物感測器
  • 晶片實驗室技術

第7章 全球生物感測器診斷市場：按分銷管道分類

  • 直銷
  • 線上銷售
  • 藥局
  • 銷售代理
  • 醫療服務提供方
  • 第三方供應商

第8章 全球生物感測器診斷市場：按應用分類

  • 血糖監測
  • 感染疾病檢測
  • 心臟生物標記檢測
  • 癌症診斷
  • 膽固醇檢測
  • 藥物發現與開發
  • 其他用途

第9章 全球生物感測器診斷市場：依最終用戶分類

  • 醫院
  • 診斷檢查室
  • 居家醫療環境
  • 研究機構
  • 製藥公司
  • 生技公司
  • 其他最終用戶

第10章 全球生物感測器診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Medtronic plc
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Nova Biomedical
  • AgaMatrix Inc.
  • Dexcom, Inc.
  • Ascensia Diabetes Care
  • Senseonics Holdings, Inc.
  • EKF Diagnostics Holdings plc
  • Universal Biosensors, Inc.
  • PerkinElmer, Inc.
  • Honeywell International Inc.
  • GE Healthcare
  • Nipro Corporation
Product Code: SMRC34764

According to Stratistics MRC, the Global Biosensor Diagnostics Market is accounted for $28.6 billion in 2026 and is expected to reach $89.4 billion by 2034 growing at a CAGR of 15.3% during the forecast period. Biosensor diagnostics refer to analytical devices that combine a biological recognition element including enzymes, antibodies, nucleic acids, or whole cells with a physicochemical transducer to detect and quantify biological analytes in clinical, environmental, food safety, and research contexts. They operate through electrochemical, optical, piezoelectric, or thermal detection principles to generate signals proportional to target analyte concentration. Common applications include continuous glucose monitoring, infectious disease detection, cardiac biomarker quantification, and cancer diagnostic screening in point-of-care and laboratory settings.

Market Dynamics:

Driver:

Point-of-Care Diagnostics Demand

Point-of-care diagnostics demand is the primary market driver as healthcare systems globally prioritize decentralized testing capabilities that reduce laboratory processing delays and enable immediate clinical decision-making. Biosensor-based rapid test devices have demonstrated clinical accuracy comparable to laboratory analyzers for glucose, troponin, and infectious pathogen detection. Growing prevalence of chronic diseases requiring continuous monitoring, particularly diabetes, is generating sustained consumable and device replacement revenue streams for biosensor manufacturers serving home care and ambulatory settings.

Restraint:

Sensor Accuracy and Calibration Limitations

Sensor accuracy and calibration limitations represent an ongoing technical restraint, particularly for continuous wearable biosensors operating across varying physiological conditions including perspiration, body temperature fluctuations, and user movement artifacts. Electrochemical sensor drift over extended wear periods reduces clinical-grade reliability, requiring frequent recalibration or replacement that increases user burden. Regulatory requirements for demonstrating clinical equivalence to laboratory reference methods impose demanding validation study requirements that elevate development costs and extend time-to-market timelines.

Opportunity:

Wearable Continuous Monitoring Markets

Wearable continuous monitoring represents an expansive growth opportunity as miniaturized biosensor integration with consumer wearable platforms creates multi-billion-dollar addressable markets beyond traditional clinical diagnostics. Continuous glucose monitor adoption is expanding from Type 1 diabetes into Type 2 and pre-diabetes wellness monitoring. Sweat-based electrochemical biosensors capable of non-invasive electrolyte and metabolite monitoring are entering commercial development, with sports performance and remote patient monitoring applications generating substantial investor and strategic partner interest.

Threat:

Counterfeit and Low-quality Competition

Counterfeit and low-quality biosensor product proliferation poses a significant market integrity threat, as unregulated manufacturers in developing markets supply non-validated diagnostic devices at substantially lower price points, undermining clinical confidence in biosensor diagnostics broadly. Regulatory enforcement capacity limitations in major emerging market economies allow substandard devices to circulate across hospital and pharmacy distribution channels. Competitive pricing pressure from low-quality products erodes premium biosensor manufacturer margins and complicates evidence-based technology differentiation arguments.

Covid-19 Impact:

COVID-19 transformed the biosensor diagnostics market by generating unprecedented demand for rapid antigen and antibody detection biosensor devices, driving manufacturing capacity expansion and regulatory emergency use authorization precedents. Pandemic-era investments in point-of-care testing infrastructure have persisted structurally in healthcare systems. Post-pandemic, respiratory pathogen biosensor applications and wearable patient monitoring solutions continue benefiting from institutionalized remote care models established during the emergency period.

The nanomechanical biosensors segment is expected to be the largest during the forecast period

The nanomechanical biosensors segment is expected to account for the largest market share during the forecast period, due to superior sensitivity enabling ultra-low analyte detection thresholds critical for cancer biomarker and pathogen diagnostics applications. Nanomechanical cantilever and resonator platforms demonstrate femtomolar detection capabilities unachievable by conventional electrochemical designs. Growing integration of nanomechanical principles into next-generation laboratory analyzers and research diagnostic instruments is driving sustained academic and clinical laboratory procurement.

The enzyme-based biosensors segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the enzyme-based biosensors segment is predicted to witness the highest growth rate, driven by expanding continuous glucose monitoring device adoption, growing point-of-care lactate and uric acid testing applications, and novel enzyme biosensor development for environmental toxin detection. Enzyme immobilization technology improvements are extending sensor operational lifespans and reducing performance variability. Major diagnostic manufacturers are intensifying investment in enzyme biosensor consumable platforms supporting recurring revenue subscription business models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to high diabetes prevalence driving continuous glucose monitor adoption, strong reimbursement coverage for home diagnostics, and leading biosensor technology development infrastructure. The U.S. FDA's established medical device regulatory pathway facilitates biosensor commercialization timelines. Companies including Abbott Laboratories and Dexcom, Inc. maintain dominant market positions through continuous product iteration and expanding wearable diagnostic platform portfolios.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding diabetic patient populations in India and China, growing point-of-care diagnostic infrastructure investment, and government programs supporting domestic medical device manufacturing. China's National Medical Products Administration has streamlined in-vitro diagnostic device approval procedures, accelerating biosensor product launches. Regional manufacturing cost advantages are attracting biosensor production capacity relocations from Western markets.

Key players in the market

Some of the key players in Biosensor Diagnostics Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Medtronic plc, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Nova Biomedical, AgaMatrix Inc., Dexcom, Inc., Ascensia Diabetes Care, Senseonics Holdings, Inc., EKF Diagnostics Holdings plc, Universal Biosensors, Inc., PerkinElmer, Inc., Honeywell International Inc., GE Healthcare, and Nipro Corporation.

Key Developments:

In March 2026, Siemens Healthineers announced a strategic partnership to integrate AI-driven biosensor diagnostic data analytics into hospital clinical decision support workflow platforms.

In February 2026, Dexcom, Inc. received FDA clearance for its over-the-counter continuous glucose monitoring biosensor targeting non-insulin-dependent diabetes and wellness monitoring segments.

In October 2025, Senseonics Holdings, Inc. initiated commercialization of its 365-day implantable glucose biosensor in European markets following CE mark approval for extended wear.

Product Types Covered:

  • Electrochemical Biosensors
  • Optical Biosensors
  • Piezoelectric Biosensors
  • Thermal Biosensors
  • Nanomechanical Biosensors
  • Wearable Biosensors
  • Other Product Types

Technologies Covered:

  • Enzyme-based Biosensors
  • Immunosensors
  • DNA Biosensors
  • Nano-biosensors
  • Microfluidic Biosensors
  • Lab-on-a-chip Technologies

Distribution Channels Covered:

  • Direct Sales
  • Online Sales
  • Pharmacies
  • Distributors
  • Healthcare Providers
  • Third-party Vendors

Applications Covered:

  • Glucose Monitoring
  • Infectious Disease Detection
  • Cardiac Biomarker Detection
  • Cancer Diagnostics
  • Cholesterol Testing
  • Drug Discovery & Development
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Home Care Settings
  • Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Biosensor Diagnostics Market, By Product Type

  • 5.1 Electrochemical Biosensors
  • 5.2 Optical Biosensors
  • 5.3 Piezoelectric Biosensors
  • 5.4 Thermal Biosensors
  • 5.5 Nanomechanical Biosensors
  • 5.6 Wearable Biosensors
  • 5.7 Other Product Types

6 Global Biosensor Diagnostics Market, By Technology

  • 6.1 Enzyme-based Biosensors
  • 6.2 Immunosensors
  • 6.3 DNA Biosensors
  • 6.4 Nano-biosensors
  • 6.5 Microfluidic Biosensors
  • 6.6 Lab-on-a-chip Technologies

7 Global Biosensor Diagnostics Market, By Distribution Channel

  • 7.1 Direct Sales
  • 7.2 Online Sales
  • 7.3 Pharmacies
  • 7.4 Distributors
  • 7.5 Healthcare Providers
  • 7.6 Third-party Vendors

8 Global Biosensor Diagnostics Market, By Application

  • 8.1 Glucose Monitoring
  • 8.2 Infectious Disease Detection
  • 8.3 Cardiac Biomarker Detection
  • 8.4 Cancer Diagnostics
  • 8.5 Cholesterol Testing
  • 8.6 Drug Discovery & Development
  • 8.7 Other Applications

9 Global Biosensor Diagnostics Market, By End User

  • 9.1 Hospitals
  • 9.2 Diagnostic Laboratories
  • 9.3 Home Care Settings
  • 9.4 Research Institutes
  • 9.5 Pharmaceutical Companies
  • 9.6 Biotechnology Firms
  • 9.7 Other End Users

10 Global Biosensor Diagnostics Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Abbott Laboratories
  • 13.2 Roche Diagnostics
  • 13.3 Siemens Healthineers
  • 13.4 Medtronic plc
  • 13.5 Danaher Corporation
  • 13.6 Thermo Fisher Scientific Inc.
  • 13.7 Bio-Rad Laboratories, Inc.
  • 13.8 Nova Biomedical
  • 13.9 AgaMatrix Inc.
  • 13.10 Dexcom, Inc.
  • 13.11 Ascensia Diabetes Care
  • 13.12 Senseonics Holdings, Inc.
  • 13.13 EKF Diagnostics Holdings plc
  • 13.14 Universal Biosensors, Inc.
  • 13.15 PerkinElmer, Inc.
  • 13.16 Honeywell International Inc.
  • 13.17 GE Healthcare
  • 13.18 Nipro Corporation

List of Tables

  • Table 1 Global Biosensor Diagnostics Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Biosensor Diagnostics Market Outlook, By Product Type (2023-2034)($MN)
  • Table 3 Global Biosensor Diagnostics Market Outlook, By Electrochemical Biosensors (2023-2034)($MN)
  • Table 4 Global Biosensor Diagnostics Market Outlook, By Optical Biosensors (2023-2034)($MN)
  • Table 5 Global Biosensor Diagnostics Market Outlook, By Piezoelectric Biosensors (2023-2034)($MN)
  • Table 6 Global Biosensor Diagnostics Market Outlook, By Thermal Biosensors (2023-2034)($MN)
  • Table 7 Global Biosensor Diagnostics Market Outlook, By Nanomechanical Biosensors (2023-2034)($MN)
  • Table 8 Global Biosensor Diagnostics Market Outlook, By Wearable Biosensors (2023-2034)($MN)
  • Table 9 Global Biosensor Diagnostics Market Outlook, By Other Product Types (2023-2034)($MN)
  • Table 10 Global Biosensor Diagnostics Market Outlook, By Distribution Channel (2023-2034)($MN)
  • Table 11 Global Biosensor Diagnostics Market Outlook, By Direct Sales (2023-2034)($MN)
  • Table 12 Global Biosensor Diagnostics Market Outlook, By Online Sales (2023-2034)($MN)
  • Table 13 Global Biosensor Diagnostics Market Outlook, By Pharmacies (2023-2034)($MN)
  • Table 14 Global Biosensor Diagnostics Market Outlook, By Distributors (2023-2034)($MN)
  • Table 15 Global Biosensor Diagnostics Market Outlook, By Healthcare Providers (2023-2034)($MN)
  • Table 16 Global Biosensor Diagnostics Market Outlook, By Third-party Vendors (2023-2034)($MN)
  • Table 17 Global Biosensor Diagnostics Market Outlook, By Other Distribution Channels (2023-2034)($MN)
  • Table 18 Global Biosensor Diagnostics Market Outlook, By Technology (2023-2034)($MN)
  • Table 19 Global Biosensor Diagnostics Market Outlook, By Enzyme-based Biosensors (2023-2034)($MN)
  • Table 20 Global Biosensor Diagnostics Market Outlook, By Immunosensors (2023-2034)($MN)
  • Table 21 Global Biosensor Diagnostics Market Outlook, By DNA Biosensors (2023-2034)($MN)
  • Table 22 Global Biosensor Diagnostics Market Outlook, By Nano-biosensors (2023-2034)($MN)
  • Table 23 Global Biosensor Diagnostics Market Outlook, By Microfluidic Biosensors (2023-2034)($MN)
  • Table 24 Global Biosensor Diagnostics Market Outlook, By Lab-on-a-chip Technologies (2023-2034)($MN)
  • Table 25 Global Biosensor Diagnostics Market Outlook, By Other Technologies (2023-2034)($MN)
  • Table 26 Global Biosensor Diagnostics Market Outlook, By Application (2023-2034)($MN)
  • Table 27 Global Biosensor Diagnostics Market Outlook, By Glucose Monitoring (2023-2034)($MN)
  • Table 28 Global Biosensor Diagnostics Market Outlook, By Infectious Disease Detection (2023-2034)($MN)
  • Table 29 Global Biosensor Diagnostics Market Outlook, By Cardiac Biomarker Detection (2023-2034)($MN)
  • Table 30 Global Biosensor Diagnostics Market Outlook, By Cancer Diagnostics (2023-2034)($MN)
  • Table 31 Global Biosensor Diagnostics Market Outlook, By Cholesterol Testing (2023-2034)($MN)
  • Table 32 Global Biosensor Diagnostics Market Outlook, By Drug Discovery & Development (2023-2034)($MN)
  • Table 33 Global Biosensor Diagnostics Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 34 Global Biosensor Diagnostics Market Outlook, By End User (2023-2034)($MN)
  • Table 35 Global Biosensor Diagnostics Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 36 Global Biosensor Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034)($MN)
  • Table 37 Global Biosensor Diagnostics Market Outlook, By Home Care Settings (2023-2034)($MN)
  • Table 38 Global Biosensor Diagnostics Market Outlook, By Research Institutes (2023-2034)($MN)
  • Table 39 Global Biosensor Diagnostics Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 40 Global Biosensor Diagnostics Market Outlook, By Biotechnology Firms (2023-2034)($MN)
  • Table 41 Global Biosensor Diagnostics Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.